With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.57184-25-5,1-(Cyclopropylmethyl)piperazine,as a common compound, the synthetic route is as follows.
57184-25-5, Example 279 Synthesis of 3-[1-{4-[2-(4-Cyclopropylmethyl-piperazin-1-yl)-2-oxo-ethyl]-3,5-dimethyl-1H-pyrrol-2-yl }-meth-(Z)-ylidene]-5-(2,6-dichloro-phenylmethanesulfonyl)-1,3-dihydro-indol-2-one A mixture of {5-[5-(2,6-dichloro-phenylmethanesulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-acetic acid (210 mg, 0.4 mmol), HOBt (54 mg, 1 eq.) and EDAC (77 mg, 1 eq.) in DMF (1.5 mL) was stirred at rt for 30 mins. To the mixture was added 1-cyclopropylmethyl-piperazine (112 mg, 2 eq.) in DMF (1.5 mL). After stirring at rt for overnight, the precipitate was collected by vacuum filtration, washed with water, sodium bicarbonate and water and then dried to give 240 mg (94%) of the titled compound. 1H-NMR (400 MHz, DMSO-d6) delta 13.48 (s, 1H, NH), 11.28 (s, 1H, NH), 8.19 (s, 1H), 7.77 (s, 1H), 7.5 (d, 1H), 7.48 (s, 1H), 7.39 (m, 2H), 7.02 (d, J=8 Hz, 1H), 4.86 (s, 2H), 3.54 (m, 2H), 3.51 (s, 2H), 3.47 (m, 2H), 2.4 (m, 4H), 2.27 (s, 3H, CH3), 2.24 (s, 3H, CH3), 2.19 (m, 2H), 0.82 (m, 1H), 0.46 (m, 2H), 0.07 (m, 2H). MS m/z 639 [M-1].
As the paragraph descriping shows that 57184-25-5 is playing an increasingly important role.
Reference£º
Patent; SUGEN, INC.; US2003/125370; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics